Which Healthcare ETF Is the Better Buy: Simplify's Mission-Driven PINK or First Trust's Biotech FBT?

First Trust NYSE Arca Biotechnology Index Fund tracks a concentrated index of 30 biotech stocks, while Simplify Health Care ETF is actively managed with broader healthcare exposure. Simplify has a lower expense ratio and a significantly lower maximum drawdown over the past five years; the article gives no specific figures for either comparison.

Analysis

The comparison is primarily a portfolio-construction signal, not evidence that the broader fund will outperform. A 30-stock biotech index is likely to carry more idiosyncratic clinical, funding, and trial-event risk; broader healthcare exposure can dilute those shocks, but may also dilute upside when biotech risk appetite turns. The reported five-year drawdown advantage is backward-looking and regime-dependent, not proof of lower forward risk. Lower fees are a durable relative benefit only if exposures and implementation are otherwise comparable.

Over days to weeks, the historical drawdown and fee framing may attract defensive reallocations, but the article provides no flows, holdings, liquidity, or valuation data to establish a near-term catalyst. Over 1–3 months, compare current sector weights and performance attribution before treating the funds as substitutes. Over 6–18 months, biotech could outperform sharply if financing conditions improve or clinical and commercial catalysts restore risk appetite; that would make the concentrated fund’s higher volatility a feature rather than a flaw. Conversely, healthcare policy pressure or a broad risk-off move could favor diversification, though not necessarily eliminate sector-wide exposure. The contrarian point: lower past drawdown may reflect the measurement window and mix of healthcare subsectors, while concentration can be valuable when biotech-specific catalysts broaden. No compelling directional trade follows from the comparison alone.

Key Decisions for Investors

• Do not rotate solely on the reported five-year drawdown. Before reallocating, verify current holdings, biotech exposure, concentration, tracking or active-management approach, trading liquidity, and the exact expense ratios.
• For investors seeking lower biotech-specific event risk, consider the Simplify Health Care ETF as a broader exposure, but treat it as a portfolio-risk choice rather than a forecast of superior returns.
• Keep the First Trust NYSE Arca Biotechnology Index Fund as the higher-beta expression only when willing to underwrite biotech catalyst and financing risk; reassess if clinical setbacks or tighter funding conditions weaken the sector thesis.
• Watch relative flows, holdings-based sector attribution, and biotech financing and clinical news over the next 1–3 months. A sustained biotech-led rebound would challenge the defensive allocation case; renewed drawdown or worsening sector fundamentals would reinforce it.